News | Left Atrial Appendage (LAA) Occluders | October 28, 2015

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

Device gives European surgeons a new option for soft tissue closure, including the left atrial appendage

Sentreheart, Lariat Surgical LAA Suture Delivery Device, left atrial appendage closure, CE Mark approval, Europe

Image courtesy of SentreHeart

October 28, 2015 — SentreHeart Inc. announced that it has received CE Mark approval for the Lariat Surgical Left Atrial Appendage (LAA) Suture Delivery Device. The Lariat Surgical LAA device is a suture-based solution for soft tissue closure, including the LAA. European surgeons can now offer their patients precise, user-controlled delivery of a 50mm pre-tied suture loop through traditional open surgical procedures or through an access port as small as 5mm.

The device compliments the company’s innovative soft tissue closure technology by leveraging the Lariat’s low-profile delivery, designed to be compatible with a broad array of surgical approaches for LAA or other soft tissue closure. Features of the Lariat include an easy-to-use 50mm snare that is compatible with access as small as 5mm, a malleable shaft design for ease of use in delivery from different access locations and an integrated suture-tightening system to reduce the risk of operator variability during closure. The surgeon, while under direct visualization, can guide the snare loop over soft tissue, including the left atrial appendage, confirm its exact closure location and deploy the pre-tied suture, resulting in immediate, complete ligation without leaving any metal or clip behind.

Unlike current surgical closure solutions, including staplers and clips, the Lariat Surgical LAA device uses a common polyester suture, which may prevent any metal-to-tissue interaction. Additionally, its low-profile design will give surgeons greater control in suture placement location and is designed to be compatible with open-chest, thoracotomy or port access procedures.

Krzysztof Bartus, M.D., Ph.D., associate professor of cardiac surgery at Jagiellonian University Krakow, Poland stated, “The Lariat Surgical device is an elegant surgical closure solution, combining the best of all the current approaches into a single device. The new device enables flexibility in my approach and access to close tissue where I want, with the additional confidence that it will remain closed. These are important characteristics when closing soft tissue such as the left atrial appendage.”

For more information: www.sentreheart.com

Related Content

J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib
News | Left Atrial Appendage (LAA) Occluders| January 18, 2018
January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders| October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
Overlay Init